Renaissance Technologies
DAWN

Renaissance Technologies’s Day One Biopharmaceuticals DAWN Stock Holding History

Renaissance Technologies’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,296,984
Closed -$27.8M – 3273
2026
Q1 		$27.8M Sell
1,296,984
-8,100
-0.6% -$114K 0.04% 524
2025
Q4 		$12.2M Buy
1,305,084
+399,608
+44% +$3.34M 0.02% 826
2025
Q3 		$6.38M Sell
905,476
-95,064
-10% -$654K 0.01% 1349
2025
Q2 		$6.5M Buy
1,000,540
+652,100
+187% +$4.49M 0.01% 1348
2025
Q1 		$2.76M Buy
348,440
+104,700
+43% +$1.13M ﹤0.01% 1793
2024
Q4 		$3.09M Buy
243,740
+148,900
+157% +$2.07M ﹤0.01% 1755
2024
Q3 		$1.32M Buy
94,840
+22,700
+31% +$324K ﹤0.01% 2282
2024
Q2 		$994K Buy
+72,140
New +$1.06M ﹤0.01% 2326
2023
Q3 		– Sell
-139,164
Closed -$1.66M – 3732
2023
Q2 		$1.66M Sell
139,164
-239,936
-63% -$3.13M ﹤0.01% 2119
2023
Q1 		$5.07M Buy
379,100
+231,674
+157% +$4.53M 0.01% 1468
2022
Q4 		$3.17M Buy
147,426
+49,526
+51% +$1.02M ﹤0.01% 1780
2022
Q3 		$1.96M Sell
97,900
-18,730
-16% -$398K ﹤0.01% 2023
2022
Q2 		$2.09M Buy
+116,630
New +$1.2M ﹤0.01% 2152

Other funds holding DAWN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies's DAWN Position: Q2 2026 in Review

Renaissance Technologies sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 1,296,984 shares — an estimated $27.8M sold.

Renaissance Technologies first reported a position in DAWN in Q2 2022 and held it in 13 quarters. The position peaked at $27.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

  • Renaissance Technologies reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 1,296,984 Day One Biopharmaceuticals shares in Q2 2026, an estimated $27.8M.
  • Renaissance Technologies first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 13 quarters.
  • Renaissance Technologies's Day One Biopharmaceuticals position peaked at $27.8M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.